Inventor
CLADER JOHN W
US55 patents
⚠️ This page may combine multiple inventors who share the name “CLADER JOHN W”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCHERING CORP
42 patentsUSRE37721EMay 28, 2002
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
SCHERING CORP99 citations99
US5846966ADec 8, 1998
Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
SCHERING CORP171 citations99
US5883096AMar 16, 1999
Muscarinic antagonists
SCHERING CORP164 citations98
US6689765B2Feb 10, 2004
Piperazine derivatives useful as CCR5 antagonists
SCHERING CORP71 citations97
US6391865B1May 21, 2002
Piperazine derivatives useful as CCR5 antagonists
SCHERING CORP94 citations97
US6037352AMar 14, 2000
Muscarinic antagonists
SCHERING CORP90 citations97
US5889006AMar 30, 1999
Muscarinic antagonists
SCHERING CORP123 citations97
US5656624AAug 12, 1997
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
SCHERING CORP115 citations97
US6387930B1May 14, 2002
Piperidine derivatives useful as CCR5 antagonists
SCHERING CORP76 citations96
US6294554B1Sep 25, 2001
Muscarinic antagonists
SCHERING CORP70 citations96
US5698548ADec 16, 1997
Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
SCHERING CORP88 citations96
US5688787ANov 18, 1997
Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
SCHERING CORP90 citations96
US6043255AMar 28, 2000
Muscarinic antagonists
SCHERING CORP50 citations95
US5238950AAug 24, 1993
Inhibitors of platelet-derived growth factor
SCHERING CORP135 citations95
US6969719B2Nov 29, 2005
Polycyclic guanine phosphodiesterase V inhibitors
SCHERING CORP59 citations94
US7208486B2Apr 24, 2007
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP16 citations93
US7122675B2Oct 17, 2006
Gamma secretase inhibitors
SCHERING CORP24 citations92
US6900329B2May 31, 2005
MCH antagonists and their use in the treatment of obesity
SCHERING CORP18 citations92
US6602885B2Aug 5, 2003
Piperidine derivatives useful as CCR5 antagonists
SCHERING CORP21 citations92
US6288068B1Sep 11, 2001
Muscarinic antagonists
SCHERING CORP22 citations91
US6472394B1Oct 29, 2002
MCH antagonists and their use in the treatment of obesity
SCHERING CORP24 citations89
USRE42461EJun 14, 2011
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
SCHERING CORP7 citations84
US7368562B2May 6, 2008
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP10 citations84
US7235543B2Jun 26, 2007
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP13 citations84
US5302716AApr 12, 1994
Fused benzazepines
SCHERING CORP11 citations74
US4973586ANov 27, 1990
Fused benzazepines, compositions of, and medical use thereof
SCHERING CORP18 citations74
US7384944B2Jun 10, 2008
Piperazine derivatives useful as CCR5 antagonists
SCHERING CORP6 citations73
US6943171B2Sep 13, 2005
Polycyclic guanine derivative phosphodiesterase V inhibitors
SCHERING CORP11 citations73
US6498168B2Dec 24, 2002
Muscarinic antagonists
SCHERING CORP5 citations73
US5362728ANov 8, 1994
4,5-bridged-2,3,4,5-tetrahydro-1H-3-benzazepine-7-ols and derivatives and compositions and methods employing such compounds
SCHERING CORP7 citations73
US7256186B2Aug 14, 2007
Gamma secretase inhibitors
SCHERING CORP8 citations71
US7459442B2Dec 2, 2008
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP3 citations63
US7192944B2Mar 20, 2007
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP4 citations63
US5374722ADec 20, 1994
Bridged benzazepines
SCHERING CORP5 citations63
US5416118AMay 16, 1995
Bicyclic amides as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
SCHERING CORP3 citations58
US7741289B2Jun 22, 2010
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP0 citations52
US7732413B2Jun 8, 2010
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP0 citations52
US7452891B2Nov 18, 2008
MCH antagonists and their use in the treatment of obesity
SCHERING CORP0 citations52
US7378518B2May 27, 2008
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP0 citations52
US7368563B2May 6, 2008
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
SCHERING CORP0 citations52
US6689783B2Feb 10, 2004
Aryl oxime-piperazines useful as CCR5 antagonists
SCHERING CORP6 citations52
US7998958B2Aug 16, 2011
Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
SCHERING CORP0 citations51
ASBEROM THEODROS
3 patentsUS8759337B2Jun 24, 2014
Gamma secretase modulators
ASBEROM THEODROS4 citations71
US8067621B2Nov 29, 2011
Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
ASBEROM THEODROS5 citations60
US8569521B2Oct 29, 2013
Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
ASBEROM THEODROS2 citations59
SCHERING PLOUGH CORP
1 patentHOFFMANN LA ROCHE
1 patentWU WEN-LIAN
1 patentPHARACOPEIA DRUG DISCOVERY INC
1 patentZHU ZHAONING
1 patentShowing the top 50 of 55 patents by PatentIndex Score.